Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
9 hedge funds and large institutions have $1.67M invested in Sonnet BioTherapeutics in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
3% more capital invested
Capital invested by funds: $1.63M → $1.67M (+$41K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
36% less funds holding
Funds holding: 14 → 9 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
| 2 |
State Street
Boston,
Massachusetts
|
+$109K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$13.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$255K |
| 2 |
VF
Virtu Financial
New York
|
-$146K |
| 3 |
BlackRock
New York
|
-$131K |
| 4 |
Bank of New York Mellon
New York
|
-$46K |
| 5 |
Jane Street
New York
|
-$39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $1.11M | +$1.01M | +230 | +418% |
|
|
2
BlackRock
New York
| $290K | -$131K | -30 | -29% |
|
|
3
State Street
Boston,
Massachusetts
| $99K | +$109K | +25 | New |
|
4
T. Rowe Price Associates
Baltimore,
Maryland
| $71K | – | – | – |
|
|
ASN
5
Advisory Services Network
Atlanta,
Georgia
| $53K | +$13.1K | +3 | +27% |
|
6
Geode Capital Management
Boston,
Massachusetts
| $24K | – | – | – |
|
|
MSFS
7
Main Street Financial Solutions
Newtown,
Pennsylvania
| $17K | – | – | – |
|
|
IA
8
IFP Advisors
Tampa,
Florida
| $3K | – | – | – |
|
9
Citigroup
New York
| $2K | – | – | – |
|
10
Morgan Stanley
New York
| $2K | – | – | – |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$255K | -46 | Closed |
|
|
VF
12
Virtu Financial
New York
| – | -$146K | -26 | Closed |
|
|
13
Bank of New York Mellon
New York
| – | -$46K | -8 | Closed |
|
|
14
Jane Street
New York
| – | -$39K | -7 | Closed |
|
|
SC
15
Scholtz & Company
Stamford,
Connecticut
| – | -$23K | -4 | Closed |
|
16
UBS Group
Zurich,
Switzerland
| – | -$10K | -2 | Closed |
|
|
TRCT
17
Tower Research Capital (TRC)
New York
| – | -$1K | – | – |
|
SONN Hedge Fund Activity: Q2 2021 in Review
9 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2021, worth a combined $1.67M — up 2.5% from $1.63M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SONN and 1 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $1.01M. The largest seller was Citadel Advisors, exiting entirely with an estimated $255K sold.
- 9 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2021, down from 14 in Q1 2021.
- Funds reported $1.67M of Sonnet BioTherapeutics stock for Q2 2021, up 2.5% quarter-over-quarter.
- 1 fund opened new Sonnet BioTherapeutics positions in Q2 2021 and 6 closed out, a net change of -5 holders.
- The largest Sonnet BioTherapeutics buyer in Q2 2021 was Vanguard Group, an estimated $1.01M added.
- The largest Sonnet BioTherapeutics seller in Q2 2021 was Citadel Advisors, an estimated $255K sold.
Based on aggregated 13F filings for Q2 2021.